Importantly, co-administration of inhibitors (BGB324, NS398, AH-6809, or BAY-u3405) inhibited the rGas6-induced reduction in the mRNA expression levels of activated fibroblast markers, such as collagen type 1, fibronectin, and α-SMA, as well as invasive fibroblast phenotype-mediating factors, such as Has2, CD44, MMP9, MMP12, and MMP14, in primary fibroblasts at 14 days post-BLM treatment (Fig. 6c and d). The gene discussed is CD44; the disease is Bloom syndrome.